The market for diabetic foot ulcer treatment market will grow from $302 million in 2012 to $1.58 billion by the end of 2017, at a considerable compound annual growth rate (CAGR) of 39.9 percent, according to a new report from research and consulting firm GlobalData.
The report, OpportunityAnalyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2017, states that out of the six major markets: the United States, France, Germany, Italy, Spain and the United Kingdom.
The United States contributed to the majority of the sales in 2012, generating an estimated $238 million. Moreover, the U.S. market will continue to hold this status in 2017, when it will represent a whopping 85 percent share of the global market with sales of around $1.34 billion.
A large portion of the growth will due to the pharmaceutical portion of the market. GlobalData highlighted the introduction of three novel wound-healing agents, Macrocure’s CureXcell, Derma Sciences’ DSC127 and Olympus Biotech’s trafermin as key contributors to the growth.
“In addition to the anticipated arrival of these key products in the DFU marketplace, an increased emphasis will also be placed on the cost-effectiveness of advanced DFU treatments in preventing serious complications, such as infection, amputation and death,” said Dr. Haylyn Wong, GlobalData’s analyst covering Cardiovascular and Metabolic Disorders. “This will prove a particularly important driver behind the market, as the number of patients suffering from DFU is also expected to increase with the rising global prevalence of diabetes.”
